Pre-Clinical Intelligence

1. The structure of competitors’ pre-clinical pipeline
2. Identifying companies at the forefront of the development of new therapies
3. KOLs used by competitors to assist them in the pre-clinical pipeline
4. Likely timing of developments in pre-clinical stages
5. The key product attributes on which the competitors intend to differentiate the product
6. Understanding potential differences between the US and European markets in terms of the development of new therapies